gip glp 1 agonist tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Response in Type 2 Diabetes and Atherosclerosis Frontiers | GLP-1/GIP dual agonist
Description
Volz A, Gke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, Gke B
doi:10.7150/ijbs.59965 This issue Cite Review 1
In 2019, the FDA approved Rybelsus (a semaglutide) as the first oral GLP-1 for Type 2 diabetes
Decreased appetite, which is an expected pharmacological effect rather than an adverse event in the research context
Interpretation is limited by the predominance of potentially overlapped retrospective data and minimal randomized evidence
